Tedizolid, also known as TR-700, DA-7157, Torezolid, is an oxazolidinone-class antibiotic. Tedizolid has been approved by FDA on June 20, 2014, for the treatment of acute bacterial Skin and skin structure infections (ABSSSI). Tedizolid exerts its bacteriostatic microbial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of the bacteria.
Related Prodcuts:
Tedizolid Phosphate; Tedizolid intermediate 1; Tedizolid intermediate 2; Torezolid intermediate 3; Tedizolid intermediate H; Tedizolid Impurity